Form 4 for VIR Vir Biotechnology, Inc.
Accepted 2023-02-24 00:00:00 ET · period of report 2023-02-22 · accession 0001209191-23-013006 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-02-24 | 2023-02-23 | VIR | HANLY ANN M. | CTO | S - Sale | $25.97 | -2,302 | 117.2K | -2% | -$59.8K |
| D | 2023-02-24 | 2023-02-22 | VIR | HANLY ANN M. | CTO | A - Grant | $0.00 | +37.5K | 119.5K | +46% | $0 |
| D | 2023-02-24 | 2023-02-22 | VIR | HANLY ANN M. | CTO | A - Grant | $0.00 | +55.0K | 55.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-23 | S | D | 2,302 | $25.97 | 117,203 | D | — | — | |
| 2 | Common | Common Stock | 2023-02-22 | A | A | 37,500 | $0.00 | 119,505 | D | — | — | (F2) Includes 532 shares of common stock acquired by the reporting person on May 31, 2022 pursuant to an employee stock purchase program. |
| 3 | Derivative | Stock Option (Right to Buy) | 2023-02-22 | A | A | 55,000 | $0.00 | 55,000 | D | $27.01 · — to 2033-02-21 | 55,000 Common Stock | (F5) 25% of the shares subject to the stock option vest and become exercisable on February 22, 2024, and the remainder vest in 36 equal monthly installments thereafter. |